β-连环蛋白在多发性骨髓瘤中的表达及临床意义
[Expression and clinical significance of beta-catenin in multiple myeloma].
作者信息
Li Juan, Zhang Dian-Bao, Luo Shao-Kai, Zhao Ying, Huang Bei-Hui, Gu Jing-Li
机构信息
Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, PR China.
出版信息
Ai Zheng. 2007 Sep;26(9):1010-4.
BACKGROUND & OBJECTIVE: beta-catenin is the pivotal regulator in Wnt pathway and in charge of cellular adhesion and signal conduction. Overexpression of beta-catenin has been observed in various human tumors. This study was to investigate the expression and clinical significance of beta-catenin in multiple myeloma (MM).
METHODS
Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect mRNA and protein expression of beta-catenin in bone marrow samples from 12 newly diagnosed MM patients, 14 relapsed/refractory MM patients, and 11 healthy donors. The clinical data and treatment outcomes of the MM patient were also analyzed.
RESULTS
The positive rate and the expression level of beta-catenin mRNA were significantly lower in healthy donors than in newly diagnosed patients and relapsed/refractory patients (27.3% vs. 75.0% and 100%, P=5.01e(-4); 0.35+/-0.17 vs. 0.72+/-0.11 and 0.85+/-0.16, P=5.88e(-5)); the mRNA level of beta-catenin was significantly lower in newly diagnosed patients than in relapsed/refractory patients (P=0.045). beta-catenin protein was not detected in healthy donors; while the positive rate and the expression level of beta-catenin protein were significantly lower in newly diagnosed patients than in relapsed/refractory patients (50.0% vs. 85.7%, 0.32+/-0.11 vs. 0.21+/-0.08, P=0.039). In the 10 newly diagnosed MM patients with evaluable treatment outcomes, the positive rate of beta-catenin protein was significant lower in the 7 patients without response than in the 3 patients showed response (14.3% vs. 100%, P=0.033). The positive rate of beta-catenin protein was significant higher in the 16 Durie/Salmon stage III patients than in the 10 stage II patients (87.5% vs. 40.0%, P=0.026), and significant higher in ISS stage III patients than in stage I and II patients (100% vs. 45.5% and 33.3%, P=0.006, P=0.032). The protein level of beta-catenin was positively correlated to serum levels of beta2-MG (r=0.688, P=0.002) and lactate dehydrogenase (LDH) (r=0.502, P=0.034).
CONCLUSION
The expression of beta-catenin is related with treatment outcome, Durin-Salmon stage and ISS stage of MM, and is positively correlated to serum levels of LDH and beta2-MG.
背景与目的
β-连环蛋白是Wnt信号通路中的关键调节因子，负责细胞黏附和信号传导。在多种人类肿瘤中均观察到β-连环蛋白的过表达。本研究旨在探讨β-连环蛋白在多发性骨髓瘤（MM）中的表达及临床意义。
方法
采用逆转录聚合酶链反应（RT-PCR）和蛋白质免疫印迹法检测12例新诊断MM患者、14例复发/难治性MM患者及11例健康供者骨髓样本中β-连环蛋白的mRNA和蛋白表达。同时分析MM患者的临床资料及治疗结果。
结果
健康供者中β-连环蛋白mRNA的阳性率及表达水平显著低于新诊断患者和复发/难治性患者（27.3% 对75.0% 和100%，P = 5.01e(-4)；0.35±0.17对0.72±0.11和0.85±0.16，P = 5.88e(-5)）；新诊断患者中β-连环蛋白mRNA水平显著低于复发/难治性患者（P = 0.045）。健康供者未检测到β-连环蛋白蛋白；新诊断患者中β-连环蛋白蛋白的阳性率及表达水平显著低于复发/难治性患者（50.0% 对85.7%，0.32±0.11对0.21±0.08，P = 0.039）。在10例有可评估治疗结果的新诊断MM患者中，无反应的7例患者β-连环蛋白蛋白阳性率显著低于有反应的3例患者（14.3% 对100%，P = 0.033）。Durie/Salmon分期III期的16例患者中β-连环蛋白蛋白阳性率显著高于II期的10例患者（87.5% 对40.0%，P = 0.026），国际分期系统（ISS）III期患者显著高于I期和II期患者（100% 对45.5% 和33.3%，P = 0.006，P = 0.032）。β-连环蛋白蛋白水平与血清β2-微球蛋白（β2-MG）水平（r = 0.688，P = 0.002）和乳酸脱氢酶（LDH）水平（r = 0.502，P = 0.034）呈正相关。
结论
β-连环蛋白的表达与MM的治疗结果、Durie-Salmon分期及ISS分期相关，且与血清LDH和β2-MG水平呈正相关。
Zotero 插件